Poor compliance: The hidden risk factor
- John C. LaRosa MD
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Poor compliance with prescribed regimens remains a potent barrier to good outcomes in coronary heart disease and other chronic diseases. Such poor compliance is related to disease, patient, provider, and treatment factors and has yet to be fully understood. In general, the less complex the regimen, the better informed the patient and the physician, and the more serious the disease, the better the compliance.
That said, research information on compliance has been somewhat stagnant for several years. There have been very few new approaches that have broken new ground or significantly enhanced or altered correct approaches. It is probably necessary that future research involve nonmedical disciplines including motivational psychology and even advertising. A good deal of such research should be specifically directed toward improving compliance in asymptomatic patients who are nevertheless at substantial risk of future catastrophic events. Until we are more successful at reproducibly improving compliance in high-risk, but asymptomatic, patients, the potential benefits of regimens whose efficacy is already very clear will remain unfulfilled.
- LaRosa JC, He J, Vupputuri S: Effect of statin drug treatment on risk of coronary heart disease: a meta-analysis of randomized, controlled trials. JAMA, 1999, in press.
- Kannel W: Clinical misconceptions dispelled by epidemiological research. Circulation 1995, 92:3350–3360.
- Random House Dictionary edn. 2. New York: 1982.
- Elliott WJ: Compliance strategies. Curr Opin Nephrol Hypertens 1994, 3:271–278. CrossRef
- Delacretaz E, Michalopoulos PG, Ruiz J, et al.: Management of hyperlipidaemia after coronary revascularisation: follow up study. BMJ 1998, 316:1499.
- Shepherd J, Pratt M: Prevention of coronary heart disease in clinical practice: a commentary on current treatment patterns in six European countries in relation published recommendations. Cardiology 1996, 87:1–5. CrossRef
- Avorn J, Monette J, Lacour A, et al.: Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998, 279:1458–1462. CrossRef
- Strandberg TE, Lehto S, Pyorala A, et al.: Cholesterol lowering after participation in the Scandinavian Simvastatin Survival Study (4S) in Finland. Eur Heart J 1997, 18:1725–1727.
- Andrade SE, Walker AM, Gottlieb LK, et al.: Discontinuation of antihyperlipidemic drugs—do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995, 332:1125–1131. CrossRef
- McDermott MM, Schmitt B, Wallner E: Impact of medication nonadherence on coronary heart disease outcomes: a critical review. Arch Intern Med 1997, 157:1921–1929. CrossRef
- Luepker RV: Patient adherence: a “risk factor” for cardiovascular disease. Heart Dis Stroke 1993, 2:418–421.
- Sung JC, Nichol MB, Venturini F, et al.: Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care 1998, 4:1421–1430.
- Chockalingam A, Bacher M, Campbell N, et al.: Adherence to management of high blood pressure: recommendations of the Canadian Coalition for High Blood Pressure Prevention and Control. Can J Pub Health 1998, 89:I5-I7.
- Burke LE, Dunbar-Jacob JM, Hill MN: Compliance with cardiovascular disease prevention strategies: a review of the research. Ann Behav Med 1997, 19:239–263. CrossRef
- Nieto FJ, Alonso J, Chambless LE, et al.: Population awareness and control of hypertension and hypercholesterolemia: The Atherosclerosis Risk in Communities study. Arch Intern Med 1995, 155:677–684. CrossRef
- Poor compliance: The hidden risk factor
Current Atherosclerosis Reports
Volume 2, Issue 1 , pp 1-4
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. SUNY Health Science Center, State University of New York, Brooklyn, 450 Clarkson Avenue, 11203, Brooklyn, NY, USA